检索结果-内蒙古大学图书馆

TP039/#1520 Phase 1B dose-escalation study of ZN-C3 (wee1 inhibitor) with chemotherapy in patients with platinum-resistant ovarian, peritoneal, or fallopian tube cancer: ZN-C3 plus gemcitabine arm

引用

International Journal of Gynecological Cancer 2022年 32卷 A242-A242页

作者： Premal Thaker Anes Pasic Gary Richardson Zivko Vranjes Stanislava Prather Lukas Makris Soamnauth Misir Philippe Pultar Dimitris Voliotis Siqing Fu Washington University School of Medicine Division of Gynecologic Oncology Saint Louis USA Clinical Centre University of Sarajevo Department of Oncology Sarajevo Bosnia and Herzegovina Cabrini Hospital Malvern Medical Oncology Melbourne Australia University Clinical Centre of the Republic of Srpska Cancer Centre Banja Luka Bosnia and Herzegovina Zentalis Pharmaceuticals Clinical Operations New York USA Zentalis Pharmaceuticals Biostatistics and Statistical Programming New York USA Zentalis Pharmaceuticals Clinical Development New York USA University of Texas M.D. Anderson Cancer Center Investigational Cancer Therapeutics Houston USA

来源：评论

学校读者我要写书评

暂无评论

1411P Tusamitamab ravtansine plus ramucirumab as 2L therapy or beyond in patients with metastatic NSq NSCLC and high CEACAM5 expression (CARMEN-LC04)

引用

Annals of Oncology 2023年 34卷 S807-S807页

作者： G.K. Dy B.C. Cho J. Oliveira M.D. Isla Casado A. Blasco Cordellat M. Zemanova J. Roubec L. Vila Martinez L. Charbonnier C. Soufflet J. de Castro Carpeño Department of Medicine Roswell Park Comprehensive Cancer Center Buffalo NY USA Division of Medical Oncology Yonsei Cancer Center Yonsei University College of Medicine Seoul Republic of Korea Medical Oncology Service Early Phase Clinical Trial Unit-IPO Porto/RISE@CI-IPOP (Health Research Network Experimental Pathology and Therapeutics Group Research Center (CI-IPOP)/RISE@CI-IPOP (Health Research Network) Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center Porto Portugal Medical Oncology Department Hospital Clínico Universitario Lozano Blesa Zaragoza Spain Medical Oncology Department Hospital General de Valencia Valencia Spain Department of Oncology First Faculty of Medicine Charles University and General University Hospital in Prague Prague Czech Republic Pneumooncology Nemocnice AGEL Ostrava-Vítkovice Ostrava-Vítkovice Czech Republic Oncology Department Consorci Corporació Sanitària Parc Taulí de Sabadell Sabadell Spain Biostatistics & Programming Sanofi Chilly-Mazarin France Clinical Development Sanofi Vitry-sur-Seine France Medical Oncology Service Hospital Universitario La Paz Madrid Spain

来源：评论

学校读者我要写书评

暂无评论

90TiP Adjuvant study of amcenestrant (SAR439859) versus tamoxifen for patients with hormone receptor-positive (HR+) early breast cancer (EBC), who have discontinued adjuvant aromatase inhibitor therapy due to treatment-related toxicity (AMEERA-6)

引用

Annals of Oncology 2022年 33卷 S162-S163页

作者： G. Rossi E. Brain A. Dueck H. De Swert S.I. Marreaud A. Partridge C. Herold H. Vachon T. Spanic A. Arahmani T. Verbiest L. Wang T. Goulioti B. Malanda L.A. Carey S. Anneheim G. Paux C. Poncet D. Cameron Research & Development Department Breast International Group (BIG) - AISBL Brussels Belgium Department of Medical Oncology Institut Curie - Hôpital René Huguenin Saint-Claud France Alliance Foundation Trials (AFT) Boston MA USA Research Operations Department Breast International Group (BIG) - AISBL Brussels Belgium Medical Department European Organisation for Research and Treatment of Cancer (EORTC) Brussels Belgium Department of Medical Oncology Alliance Foundation Trials (AFT) Boston MA USA Oncology Sanofi Genzyme Cambridge MA USA Quality of Life Department European Organisation for Research and Treatment of Cancer (EORTC) Brussels Belgium Europa Donna − the European Breast Cancer Coalition Milan Italy Research Operations Department Breast International Group (BIG)-AISBL Brussels Belgium Data Management European Organisation for Research and Treatment of Cancer (EORTC) Brussels Belgium Translational Medicine and Early Development Sanofi Boston MA USA Breast International Group (BIG) - AISBL Brussels Belgium Projects Direction European Organisation for Research and Treatment of Cancer (EORTC) Brussels Belgium Division of Medical Oncology North Carolina Lineberger Comprehensive Cancer Center Chapel Hill NC USA Oncology Development Sanofi-Aventis Recherche et Developpement Vitry-sur-Seine France Biostatistics and Programming Sanofi-Aventis U.S. LLC Bridgewater MA USA Statistics European Organisation for Research and Treatment of Cancer (EORTC) Brussels Belgium University of Edinburgh Cancer Research Centre Institute of Genetics and Cancer Western General Hospital Edinburgh UK

来源：评论

学校读者我要写书评

暂无评论

19P Therapeutic targets in non-small cell lung cancer: Preclinical and human studies of carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) expression and its associated molecular landscape

引用

Annals of Oncology 2021年 32卷 S1381-S1381页

作者： J. Adam A-M. Lefebvre C. Nicolazzi C. Larois F. Attenot F. Falda-Buscaiot C. Dib N. Ternès N. Masson A-L. Bauchet B. Demers M. Chadjaa S. Sidhu C. Combeau J-C. Soria J-Y. Scoazec S. Naimi E. Angevin C. Henry Pathology Institut Gustave Roussy Villejuif France Molecular Histopathology and Bio-Imaging Translational Sciences Unit Sanofi Chilly-Mazarin France Oncology Research Sanofi R&D Sanofi Vitry-sur-Seine France Molecular Histopathology and Bio-Imaging Translational Sciences Unit Sanofi Vitry-sur-Seine France Oncology Research Department Sanofi Vitry-sur-Seine France Early Oncology Sanofi Vitry-sur-Seine France Oncology Sanofi Vitry-sur-Seine France Biostatistics and Programming Sanofi Chilly-Mazarin France IT&M Stats Sanofi Paris France Translational Medicine and Early Development/Biomarkers and Clinical Bioanalyses Sanofi Chilly-Mazarin France Early Development Oncology Sanofi Vitry-sur-Seine France Oncology Development Sanofi Vitry-sur-Seine France Pharmacology Sanofi Vitry-sur-Seine France Translational Medicine and Early Development Sanofi Vitry-sur-Seine France Drug development Department Institut Gustave Roussy Villejuif France Université Paris Saclay Institut Gustave Roussy Villejuif France Molecular and Digital Histopathology Research and Development Sanofi Vitry-sur-Seine France Early Drug Development Institut Gustave Roussy Villejuif France Oncology R&D (research) Sanofi Vitry-sur-Seine France

来源：评论

学校读者我要写书评

暂无评论

LBA35 BNT211-01: Interim results from a repeat dose escalation study of CLDN6 CAR-T cells manufactured with an automated process ± a CLDN6-encoding CAR-T cell-amplifying RNA Vaccine (CARVac)

引用

Annals of Oncology 2023年 34卷 S1274-S1275页

作者： A. Mackensen J.B.A.G. Haanen W. Alsdorf C. Koenecke E. Wagner-Drouet P. Borchmann D. Heudobler A. Busse S. Klobuch N. Kutsch F. Müller C. Bokemeyer A. Desuki F. Lueke T. Ho K. Vemuri L. Preussner B. Rengstl Ö. Türeci U. Sahin Dept. of Medicine 5 - Hematology/Oncology Universitätsklinik Erlangen Erlangen Germany Medical Oncology Dept NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital Amsterdam Netherlands Zentrum für Onkologie II. Medizinische Klinik und Poliklinik (Onkologie Hämatologie Knochenmarktransplantation mit Abteilung für Pneumologie) University Medical Center Hamburg-Eppendorf Hamburg Germany Institut für Immunologie MHH - Medizinische Hochschule Hannover Hannover Germany Zelluläre Immuntherapie und Stammzelltransplantation University Medical Center Mainz Mainz Germany Internal Medicine University Hospital Cologne Cologne Germany Department of Internal Medicine III Hematology and Oncology UKR - University Hospital Regensburg Regensburg Germany Medizinische Klinik III Charite Campus Benjamin Franklin Medizinische Klinik III Berlin Germany Medical oncology NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital Amsterdam Netherlands Department I of Internal Medicine and Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf University Hospital of Cologne Cologne Germany Internal Medicine 5 Hematology/Oncology Department Universitätsklinikums Erlangen Erlangen Germany Oncology and Hematology UKE Universitätsklinikum Hamburg-Eppendorf KMTZ Hamburg Germany 3rd Medical Department Hematology and Oncology Universitätsmedizin der Johannes Gutenberg-Universität Mainz Mainz Germany Department of Internal Medicine III Haematology and Oncology UKR - University Hospital Regensburg Regensburg Germany Clinical Pharmacology BioNTech US Cambridge MA USA Statistical Programming BioNTech US Cambridge MA USA Clinical Development BioNTech SE Mainz Germany Cell & Gene Therapies BioNTech SE Mainz Germany Chief Medical Officer BioNTech SE Mainz Germany Clinical development BioNTech SE Mainz Germany

来源：评论

学校读者我要写书评

暂无评论

713TiP A phase I study of PRT3789, a potent and selective degrader of SMARCA2 in patients with advanced or metastatic solid tumors and a SMARCA4 mutation

引用

Annals of Oncology 2023年 34卷 S493-S494页

作者： I. Dagogo-Jack A. Dowlati R. Guo M.M. Awad A. Swalduz E. Calvo V. Moreno Garcia A.A. Adjei P. Lorusso S. Punekar T.A. Leal T.A. Yap A. Italiano W. Novotny C. Tankersley S. Rowe G. Paris W. Sun A.I. Spira B. Besse Medicine Hematology/Oncology Department Massachusetts General Hospital-Surgical Oncology Division Boston MA USA Department of Hematology and Oncology University Hospitals Seidman Cancer Center and Case Western Reserve University Cleveland OH USA Gynecologic Medical Oncology Memorial Sloan Kettering Cancer Center New York NY USA Medical Oncology Dana-Farber Cancer Institute Boston MA USA Medical Oncology Centre Léon Bérard Lyon France Medical Oncology Division START Madrid-CIOCC Centro Integral Oncológico Clara Campal Madrid Spain Clinical Research Phase 1 Trials Unit START Madrid-FJD Hospital Fundación Jiménez Díaz Madrid Spain Taussig Cancer Institute Cleveland Clinic Cleveland OH USA Developmental Therapeutics Medical Oncology Yale Cancer Center New Haven CT USA Hematology and Oncology NYU Langone Health New York NY USA Hematology & Oncology Winship Cancer Institute of Emory University Atlanta GA USA Department of Investigational Cancer Therapeutics The University of Texas MD Anderson Cancer Center Houston TX USA Early Phase Trials Unit Institut Bergonié and Faculty of Medicine University of Bordeaux Bordeaux France Clinical Development Prelude Therapeutics Inc. Wilmington DE USA Clinical Operations Prelude Therapeutics Inc. Wilmington DE USA Translation Medicine Prelude Therapeutics Wilmington DE USA Biostatistics and Programming Prelude Therapeutics Wilmington DE USA Research Institute NEXT Oncology-Virginia Fairfax VA USA Department of Oncology Medicine Gustave Roussy Villejuif France

来源：评论

学校读者我要写书评

暂无评论

Cardiac Troponin I and Cardiovascular Risk in Patients With Chronic Obstructive Pulmonary Disease (vol 72, pg 1126, 2018)

引用

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY 2018年第18期72卷 2282-2282页

作者： Adamson, P. D. Anderson, J. A. Brook, R. D. Calverley, P. M. A. Celli, B. R. Cowans, N. J. Crim, C. Dixon, I. J. Martinez, F. J. Newby, D. E. Vestbo, J. Yates, J. C. Mills, N. L. British Heart Foundation Centre for Cardiovascular Science University of Edinburgh Edinburgh United Kingdom. Research & Development GSK Stockley Park Middlesex United Kingdom. Division of Cardiovascular Medicine University of Michigan Ann Arbor Michigan. Department of Medicine Clinical Sciences Centre University of Liverpool University Hospital Aintree Liverpool United Kingdom. Pulmonary and Critical Care Division Brigham and Women's Hospital Harvard Medical School Boston Massachusetts. Statistics and Programming Veramed Twickenham United Kingdom. Research & Development GSK Research Triangle Park North Carolina. Joan and Sanford I. Weill Department of Medicine Weill Cornell Medicine New York New York. Division of Infection Immunity and Centre for Respiratory Medicine and Allergy Manchester Academic Health Science Centre The University of Manchester and Manchester University NHS Foundation Trust Manchester United Kingdom. British Heart Foundation Centre for Cardiovascular Science University of Edinburgh Edinburgh United Kingdom. Electronic address: nick.mills@ed.ac.uk.

Patients with chronic obstructive pulmonary disease (COPD) have increased risk of cardiovascular events.;This study evaluated the association between high-sensitivity cardiac troponin I concentration and cardiovascular events in patients with COPD and heightened cardiovascular risk.;In a double-blind randomized controlled trial, 16,485 patients with COPD and cardiovascular disease or risk factors were randomized to once daily inhaled placebo, fluticasone furoate (100 μg), vilanterol (25 μg), or their combination. Plasma high-sensitivity cardiac troponin I concentrations were measured in a subgroup of 1,599 patients. Outcomes were on-treatment cardiovascular events and COPD exacerbations over a median of 18 months, and cardiovascular death over a median of 27 months.;Baseline plasma cardiac troponin I concentrations were above the limit of detection (1.2 ng/l) in 1,542 (96%) patients. Concentrations were unaffected by inhaled therapies at 3 months (p > 0.05). Compared with the lowest quintile (cardiac troponin <2.3 ng/l), patients in the highest quintile (≥7.7 ng/l) were at greater risk of cardiovascular events (hazard ratio [HR] 3.7; 95% confidence interval [CI]: 1.3 to 10.1; p = 0.012) and cardiovascular death (HR: 20.1; 95% CI: 2.4 to 165.2; p = 0.005) after adjustment for risk factors. By contrast, there were no differences in exacerbations between quintiles (HR: 1.1; 95% CI: 0.8 to 1.5; p = 0.548).;In patients with COPD and heightened cardiovascular risk, plasma cardiac troponin I concentrations are a specific and major indicator of future cardiovascular events and cardiovascular death. Inhaled therapies did not affect cardiac troponin I concentrations consistent with their neutral effect on mortality and cardiovascular outcomes. (Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease [SUMMIT]; NCT01313676).

关键词： cardiac troponin cardiovascular risk chronic obstructive pulmonary disease

来源：评论

学校读者我要写书评

暂无评论

Conceptual model of the VR module for “Virtual plaza for interactive presentation of Bulgarian cultural heritage”

引用

AIP Conference Proceedings 2019年第1期2172卷

作者： Angel Bachvarov Dimo Chotrov Yordan Yordanov Zlatka Uzunova 1Technical University Sofia Faculty of Mechanical Engineering Department Automation of Discrete Production Engineering Bulgaria 2Technical University Sofia Faculty of Computer Systems and Technologies Department Programming and Computer Technologies Bulgaria 3Technical University Sofia Faculty of German Engineering Education and Industrial Management Bulgaria 4Research and Development and Innovation Consortium Virtual and Augmented Reality Laboratory Bulgaria

In the last years, Virtual Reality (VR) has been established itself as a highly promising media technology for reconstruction and presentation of cultural heritage sites to a wide audience. Virtual Reality enables not only an exploration of a single artefact but of many virtual objects spatially and temporally arranged into a single scene. The users enter an artificially created space and get a feeling of being a part of it. They can perceive and interact with the objects in the virtual environment in natural way. In this paper we propose a conceptual model of the VR module for the “Virtual Plaza for Immersive Representation of Bulgarian Cultural Heritage Sites”. It contains an analysis of the possible input data and the developed workflows to help experts from the cultural heritage domain to implement various scenarios for presentation of single artefacts and complete scene par of cultural heritage site using the benefits of Virtual Reality as visualization medium.

关键词：

来源：评论

学校读者我要写书评

暂无评论

845P Vidutolimod + pembrolizumab as 2L+ treatment in patients with anti–PD-1–refractory melanoma and adrenal insufficiency: Subgroup analyses of a phase Ib study

引用

Annals of Oncology 2022年 33卷 S936-S936页

作者： J.M. Kirkwood Y. Zakharia D. Davar E. Buchbinder T. Medina A. Daud A. Ribas B. Chmielowski J.J. Niu G.T. Gibney K.A. Margolin A.J. Olszanski I. Mehmi T. Sato M. Shaheen L. Zhao D. Bobilev A.M. Krieg J. Wooldridge M. Milhem Division of Hematology/Oncology University of Pittsburgh Medical Center Pittsburgh PA USA Cancer Department Internal Medicine University of Iowa Iowa City IA USA Medicine-Medical Oncology Dana Farber Cancer Institute Boston MA USA Medicine-Medical Oncology University of Colorado Denver Aurora CO USA Medicine University of California San Francisco San Francisco CA USA Molecular and Medical Pharmacology University of California Los Angeles Los Angeles CA USA Hematology/Oncology University of California Los Angeles Los Angeles CA USA Hematology/Oncology Banner MD Anderson Cancer Center Gilbert AZ USA Medical Oncology Georgetown Lombardi Comprehensive Cancer Center Washington DC USA SJCI Melanoma Program City of Hope Comprehensive Cancer Center Santa Monica CA USA Hematology/Oncology Fox Chase Cancer Center Philadelphia PA USA Hematology/Oncology The Angeles Clinic and Research Institute Los Angeles CA USA Medical Oncology Thomas Jefferson University Philadelphia PA USA Oncology University of Arizona Tucson AZ USA Biostatistics & Programming Checkmate Pharmaceuticals Inc. Cambridge MA USA Clinical Development Checkmate Pharmaceuticals Inc. Cambridge MA USA Scientific Affairs Checkmate Pharmaceuticals Inc. Cambridge MA USA Medical Affairs Checkmate Pharmaceuticals Inc. Cambridge MA USA Internal Medicine University of Iowa Iowa City IA USA

来源：评论

学校读者我要写书评

暂无评论

277MO SAR439859, an oral selective estrogen receptor (ER) degrader (SERD), in ER+/ HER2- metastatic breast cancer (mBC): Biomarker analyses from a phase I/II study

引用

Annals of Oncology 2020年 31卷 S351-S351页

作者： S. Chandarlapaty A. Bardia S. Lord H. Linden V. Pelekanou N. Ternes J. Ming V. Boutet E. Boitier A. Gosselin J. Sang Lee W. Dos-Santos Bele A. Protopopov M. Celanovic A-L. Bauchet M. Campone Medicine Memorial Sloan Kettering Cancer Center New York NY USA Medical Oncology Massachusetts General Hospital Harvard Medical School Boston MA USA Department of Oncology University of Oxford Churchill Hospital Oxford UK Department of Medicine University of Washington Medical Center Seattle WA USA Clinical Precision Oncology-Tranlsational Medicine Early Development Sanofi Cambridge MA USA Biostatistics and Programming Sanofi Paris France Oncology Sanofi Bridgewater NJ USA TMED & Biomarkers & Clinical Bioanalyses Sanofi Paris France Precision Oncology Sanofi Cambridge MA USA Molecular Profiling Precision Oncology Sanofi Paris France Oncology-OMD Sanofi Cambridge MA USA Medical Oncology Institut de Cancérologie de l'Ouest Saint-Herblain France

来源：评论

学校读者我要写书评

暂无评论

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

请选择保存的检索档案：

请选择收藏分类：

通借通还

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：